UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 6, 2021
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
||
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on which registered
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. |
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On December 6, 2021, LuAnn Via submitted her letter of resignation, effective December 31, 2021, from her position as a Board
member, Vice Chairperson, and Chair of the Board's Audit Committee of Strata Skin Sciences, Inc. (the “Company”). This resignation is not a result of any disagreement or dispute related to Strata’s operations, accounting policies, or practices. On
the same date, Douglas Strang, a member of the Company's Board and a member of the Audit Committee, agreed to serve as Chair of the Audit Committee effective upon Ms. Via’s resignation.
| Item 7.01. |
Regulation FD Disclosure.
|
On December 9, 2021, the Company issued a press release announcing the appointment of Douglas Strang as Chair of the Audit Committee and the
resignation of LuAnn Via from her positions on the Board of the Company. The full text of such press release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits
|
| 99.1 |
Press release, dated December 9, 2021, of Strata Skin Sciences, Inc.
|
| 104 |
Cover Page Interactive Data File (embedded within the inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
Date: December 9, 2021
|
By:
|
/s/ Christopher Lesovitz
|
|
|
Christopher Lesovitz
|
|
|
|
|
Chief Financial Officer
|
-2-
Exhibit 99.1
STRATA Skin Sciences Announces Board of Directors Transition
Horsham, Pa, December 9, 2021 —STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that Douglas Strang was appointed to the Board of Directors, effective October 27, 2021. Mr. Strang will assume the role of Audit Committee Chair upon the departure of LuAnn Via, who will step
down from the Board on December 31, 2021 as part of a planned transition.
“We are delighted that Doug has join the STRATA leadership team,” said William Humphries, Chairperson of the Board of Directors at STRATA Skin Sciences. “He has
spent his extensive career in life sciences and guided a multitude of organizations through successful strategic financial and operational advancement. His experience will be vital as we continue to drive momentum worldwide for STRATA’s XTRAC
laser system within the dermatology market.”
Douglas Strang, formerly a partner at PwC, retired following a 35 year career with the firm. At the time of his retirement, he served as Global Pharmaceuticals
& Life Science Advisory Leader. Mr. Strang began in the audit practice, where he performed financial audits, primarily in the healthcare industry. He later transitioned into forensic and risk practice where he led various projects, including;
board appointed financial investigations, fraud and abuse matters in the life sciences industry and other healthcare compliance regulatory matters. He also has significant experience in the area of merger and acquisitions, where he assisted his
clients with financial due diligence and merger integration. Mr. Strang also served as the US Pharmaceutical and Life Sciences Advisory Leader from 2009, from which he transitioned to the European leader in 2019. The PwC practice he led focused on
providing value-added solutions across the Life Sciences value chain, including; M&A, R&D, manufacturing and supply chain, commercial and finance operations. Mr. Strang is a Certified Public Accountant in the Commonwealth of Pennsylvania
and holds a BS degree in accounting from Penn State University and an MBA from Villanova University.
“STRATA has an excellent opportunity for growth and expansion within the dermatology market and I am pleased to be a part of this qualified team, including
assuming the role of Audit Chair at year end,” said Mr. Strang. “It’s an exciting time for the company and believe they are well positioned as we head into 2022 and beyond.”
“On behalf of the entire Board, we want to thank LuAnn for her nine years of service and guidance on our Board,” added Mr. Humphries. “Her many contributions
have been invaluable, and we wish her well on any future endeavors.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the
treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis,
vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and
insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
Investor Contact
Jack Droogan
(203) 585-4140
ir@strataskin.com